TY - JOUR
T1 - New anticoagulants for venous thromboembolism and atrial fibrillation
T2 - what the future holds
AU - Dimitropoulos, Gerasimos
AU - Rahim, S M Zubair
AU - Moss, Alexandra Sophie
AU - Lip, Gregory Y H
PY - 2018/1
Y1 - 2018/1
N2 - INTRODUCTION: The field of anticoagulation has seen impressive progress over the last decade. The introduction of the Non Vitamin K Oral Anticoagulants (NOACs) has revolutionized practice surrounding thromboprophylaxis, treatment of thromboembolic disease and stroke prevention in atrial fibrillation (AF). However, the search for the 'holy grail' of anticoagulation, an agent that combines optimal efficacy with minimal bleeding diathesis, continues. Areas covered: In this paper we aim to summarize the current evidence from pre-clinical studies and early phase clinical trials, presenting the pharmacodynamic and pharmacokinetic properties as well as the safety and efficacy profiles of the most important antithrombotic agents in development. Expert opinion: Research focused on the development of new anticoagulation agents is rapidly expanding. Although the exploration of antithrombotic agents that act on well-established targets such factor Xa and thrombin remains the mainstay, attention has also shifted to other factors in the coagulation cascade. The evidence emerging from clinical research is growing, generating exciting possibilities in the field of anticoagulation.
AB - INTRODUCTION: The field of anticoagulation has seen impressive progress over the last decade. The introduction of the Non Vitamin K Oral Anticoagulants (NOACs) has revolutionized practice surrounding thromboprophylaxis, treatment of thromboembolic disease and stroke prevention in atrial fibrillation (AF). However, the search for the 'holy grail' of anticoagulation, an agent that combines optimal efficacy with minimal bleeding diathesis, continues. Areas covered: In this paper we aim to summarize the current evidence from pre-clinical studies and early phase clinical trials, presenting the pharmacodynamic and pharmacokinetic properties as well as the safety and efficacy profiles of the most important antithrombotic agents in development. Expert opinion: Research focused on the development of new anticoagulation agents is rapidly expanding. Although the exploration of antithrombotic agents that act on well-established targets such factor Xa and thrombin remains the mainstay, attention has also shifted to other factors in the coagulation cascade. The evidence emerging from clinical research is growing, generating exciting possibilities in the field of anticoagulation.
KW - Anticoagulation
KW - anticoagulation reversal
KW - atrial fibrillation
KW - stroke
KW - thromboembolism
KW - thromboprophylaxis
UR - http://www.scopus.com/inward/record.url?scp=85041463943&partnerID=8YFLogxK
U2 - 10.1080/13543784.2018.1416090
DO - 10.1080/13543784.2018.1416090
M3 - Review article
C2 - 29224364
SN - 1354-3784
VL - 27
SP - 71
EP - 86
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 1
ER -